Stockscreener 앱 받기
23.57
4.19%
-1.03
시간 외 거래:
24.04
0.47
+1.99%
전일 마감가:
$24.60
열려 있는:
$24.57
하루 거래량:
410.07K
Relative Volume:
0.57
시가총액:
$1.57B
수익:
$5.79M
순이익/손실:
$-199.61M
주가수익비율:
-7.8306
EPS:
-3.01
순현금흐름:
$-188.48M
1주 성능:
+4.38%
1개월 성능:
-8.18%
6개월 성능:
-0.97%
1년 성능:
+5.88%
1일 변동 폭
$23.09
$24.78
1주일 범위
$22.33
$25.24
52주 변동 폭
$14.40
$30.50
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
23.57 | 1.63B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring a 115% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
(02/11/26) Top Picks 2026: Celldex Therapeutics Inc. (CLDX) - moneyshow.com
Biotech Celldex to field investor questions at 3 conferences - Stock Titan
Celldex to Present at Upcoming Investor Conferences - GlobeNewswire
Celldex Therapeutics Breaks Below 200-Day Moving AverageNotable for CLDX - Nasdaq
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring a Potential 116% Upside in Biotech Innovation - DirectorsTalk Interviews
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis - TipRanks
Whats Radiant Logistics Incs historical returnQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Update Recap: Does Celldex Therapeutics Inc stock benefit from AI growthMarket Rally & AI Powered Market Entry Strategies - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance - Yahoo Finance
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Mixed Multi‑Year Returns - Sahm
Will Celldex Therapeutics Inc. benefit from government policyJuly 2025 Summary & Stepwise Trade Signal Guides - mfd.ru
Celldex Therapeutics (CLDX) Investor Outlook: Analysts See Over 100% Upside Potential - DirectorsTalk Interviews
Growth Report: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Pullback Review & Consistent Income Trade Recommendations - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness - Sahm
Will Celldex Therapeutics Inc. stock hit new highs in YEARWeekly Stock Recap & Pattern Based Trade Signal System - mfd.ru
Day Trade: cờ tướng họcEarnings Growth Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest - MarketBeat
Pullback Watch: Whats the fair value of Celldex Therapeutics Inc stockWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates - Sahm
Value Recap: Is Celldex Therapeutics Inc stock resilient to inflationFed Meeting & Smart Allocation Stock Tips - Bộ Nội Vụ
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Unpacking a 107.86% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Celldex Therapeutics SVPs Engage In Heavy Transactions - AOL.com
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5%Here's Why - MarketBeat
Market Pulse: Can Celldex Therapeutics Inc disrupt its industryMarket Rally & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Can Celldex Therapeutics Inc disrupt its industry2025 Geopolitical Influence & Reliable Price Action Trade Plans - baoquankhu1.vn
How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story - Sahm
Will Celldex Therapeutics Inc. stock see insider buyingPortfolio Risk Summary & Detailed Earnings Play Strategies - ulpravda.ru
Will Celldex Therapeutics Inc. stock deliver better than expected guidanceQuarterly Profit Report & Advanced Swing Trade Entry Plans - Улправда
Why Celldex Therapeutics Inc. (TCE2) stock could be top winnerJuly 2025 Chart Watch & Fast Entry High Yield Tips - Улправда
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings - Sahm
Will Celldex Therapeutics Inc. stock attract more institutional investors2025 Market Overview & Precise Swing Trade Alerts - Улправда
Can Celldex Therapeutics Inc. stock deliver surprise earnings beatStop Loss & Daily Growth Stock Investment Tips - Улправда
How Celldex Therapeutics Inc. stock trades during market volatility2025 Analyst Calls & Fast Entry Momentum Trade Alerts - Улправда
Is Celldex Therapeutics Inc. stock a good choice for value investorsMarket Sentiment Summary & Smart Allocation Stock Reports - Улправда
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company - Barchart.com
Celldex Therapeutics Builds Momentum Around Barzolvolimab And Bispecific Antibody Programs - RTTNews
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics (CLDX) Stock Analysis: Biotechnology Innovator with Over 100% Upside Potential - DirectorsTalk Interviews
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% HigherShould You Buy? - MarketBeat
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9% - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Strong Buy Ratings and Nearly 96% Upside Potential - DirectorsTalk Interviews
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 - Insider Monkey
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely - Yahoo Finance
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Celldex Therapeutics Inc 주식 (CLDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
1.24%
0.19%
자본화:
|
볼륨(24시간):